Theseus Pharmaceuticals Inc (THRX)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Timothy P. Clackson
Employees:
30
245 MAIN STREET, CAMBRIDGE, MA 02142
(857) 400-9491

Theseus Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of targeted therapies for cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Data derived from most recent annual or quarterly report
Market Cap 117.293 Million Shares Outstanding43.603 Million Avg 30-day Volume 98.262 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.3
Price to Revenue0.0 Debt to Equity0.0 EBITDA-60.624 Million
Price to Book Value1.7433 Operating Margin0.0 Enterprise Value173.827 Million
Current Ratio27.825 EPS Growth-1.171 Quick Ratio27.103
1 Yr BETA 1.5594 52-week High/Low 14.77 / 2.6 Profit Margin0.0
Operating Cash Flow Growth-47.7641 Free Cash Flow to Firm (FCFF) TTM -45.706 Million Free Cash Flow to Equity (FCFE) TTM-46.333 Million
Altman Z-Score21.697
Earnings Report2023-11-02
View SEC Filings from THRX instead.

View recent insider trading info

Theseus Pharmaceuticals Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding THRX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding THRX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-03-02 by RIVERA VICTOR
  • 4: filed on 2023-03-02 by SHAKESPEARE WILLIAM
  • 4: filed on 2023-03-02 by KERSTEIN DAVID
  • 4: filed on 2023-03-02 by DAHMS BRADFORD D.
  • 4: filed on 2023-03-02 by CLACKSON TIMOTHY P
  • 4: filed on 2023-02-21 by SHAKESPEARE WILLIAM
  • 4: filed on 2023-02-21 by RIVERA VICTOR
  • 4: filed on 2023-02-21 by KERSTEIN DAVID
  • 4: filed on 2023-02-21 by DAHMS BRADFORD D.
  • 4: filed on 2023-02-21 by CLACKSON TIMOTHY P

    • Events (8k)

  • 8-K: filed on 2023-08-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-07-13:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-09:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2023-05-25:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-11:
    Item 2.02: Results of Operations and Financial Condition
  • 8-K: filed on 2023-03-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-05:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-19:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-11:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    ORBIMED ADVISORS LLC

    ORBIMED GENESIS GP LLC

    ORBIMED CAPITAL GP VII LLC

    • Director
    • 10% Owner
    		 17,713,600 2023-07-17 2

    GORDON CARL L

    • Director
    • 10% Owner
    		 17,713,600 2023-07-17 3

    FORESITE CAPITAL MANAGEMENT V, LLC

    FORESITE CAPITAL FUND V, L.P.

    FORESITE CAPITAL OPPORTUNITY FUND V, L.P.

    FORESITE CAPITAL OPPORTUNITY MANAGEMENT V, LLC

    TANANBAUM JAMES B.

    • 10% Owner
    		 5,494,621 2023-07-17 2

    HAYDEN DONALD J JR

    • Director
    		 0 2023-06-13 2

    STEIN STEVEN H

    • Director
    		 0 2023-06-13 3

    DUKES IAIN D.

    • Director
    		 0 2023-06-13 1

    YI KATHY

    • Director
    		 0 2023-06-13 1

    CLACKSON TIMOTHY P PRESIDENT AND CEO

    • Officer
    • Director
    		 0 2023-03-01 3

    DAHMS BRADFORD D. CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2023-03-01 3

    KERSTEIN DAVID CHIEF MEDICAL OFFICER

    • Officer
    		 0 2023-03-01 2

    RIVERA VICTOR CHIEF SCIENTIFIC OFFICER

    • Officer
    		 0 2023-03-01 2

    SHAKESPEARE WILLIAM SEE REMARKS

    • Officer
    		 0 2023-03-01 2

    DALGARNO DAVID CHIEF TECHNICAL OFFICER

    • Officer
    		 130,000 2022-02-18 0

    TAKEDA PHARMACEUTICAL CO LTD

    ARIAD PHARMACEUTICALS INC

    • 10% Owner
    		 1,615,427 2021-10-12 0

    OMEGA FUND VI, L.P.

    OMEGA FUND VI GP MANAGER, LTD.

    STAMPACCHIA OTELLO

    NESSI CLAUDIO

    PASTER ANNE-MARI

    • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
    		 711,479 2021-10-12 0

    ROCK SPRINGS CAPITAL MANAGEMENT LP

    ROCK SPRINGS CAPITAL MASTER FUND LP

    ROCK SPRINGS CAPITAL LLC

    • 10% Owner
    		 1,035,969 2021-10-12 0

    GLAXOSMITHKLINE PLC

    • 10% Owner
    		 32,005,260 2015-08-07 0

    BLUM LEONARD M SR VP, CHIEF COMM. OFFICER

    • Officer
    		 158,618 2010-02-24 0

    VAGELOS P ROY

    • Director
    		 1,318,831 2008-03-14 0

    WINNINGHAM RICK E CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 43,118 2008-03-11 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    THESEUS PHARMACEUTICALS INC THRX 2023-09-29 22:15:03 UTC -0.1226 5.4426 2100000
    THESEUS PHARMACEUTICALS INC THRX 2023-09-29 21:45:04 UTC -0.1226 5.4426 2100000
    THESEUS PHARMACEUTICALS INC THRX 2023-09-29 21:15:03 UTC -0.1226 5.4426 2100000
    THESEUS PHARMACEUTICALS INC THRX 2023-09-29 20:45:05 UTC -0.1226 5.4426 2100000
    THESEUS PHARMACEUTICALS INC THRX 2023-09-29 20:15:04 UTC -0.1226 5.4426 2100000
    THESEUS PHARMACEUTICALS INC THRX 2023-09-29 19:45:04 UTC -0.1226 5.4426 2100000
    THESEUS PHARMACEUTICALS INC THRX 2023-09-29 19:15:03 UTC 0.0 0.0 2100000
    THESEUS PHARMACEUTICALS INC THRX 2023-09-29 18:45:03 UTC 0.0 0.0 2100000
    THESEUS PHARMACEUTICALS INC THRX 2023-09-29 18:15:03 UTC 0.0 0.0 2100000
    THESEUS PHARMACEUTICALS INC THRX 2023-09-29 17:45:03 UTC -0.1226 5.4426 2100000
    THESEUS PHARMACEUTICALS INC THRX 2023-09-29 17:15:04 UTC -0.1226 5.4426 2100000
    THESEUS PHARMACEUTICALS INC THRX 2023-09-29 16:45:04 UTC -0.1226 5.4426 2100000
    THESEUS PHARMACEUTICALS INC THRX 2023-09-29 16:15:03 UTC -0.1226 5.4426 2100000
    THESEUS PHARMACEUTICALS INC THRX 2023-09-29 15:45:04 UTC -0.1226 5.4426 2100000
    THESEUS PHARMACEUTICALS INC THRX 2023-09-29 15:15:04 UTC -0.1226 5.4426 2100000
    THESEUS PHARMACEUTICALS INC THRX 2023-09-29 14:45:04 UTC -0.1166 5.4366 2100000
    THESEUS PHARMACEUTICALS INC THRX 2023-09-29 14:15:04 UTC -0.1166 5.4366 2100000
    THESEUS PHARMACEUTICALS INC THRX 2023-09-29 13:45:03 UTC -0.3186 5.6386 2100000
    THESEUS PHARMACEUTICALS INC THRX 2023-09-29 13:15:04 UTC -0.3186 5.6386 2100000
    THESEUS PHARMACEUTICALS INC THRX 2023-09-29 12:45:05 UTC -0.3186 5.6386 2100000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments